154 related articles for article (PubMed ID: 11078816)
1. Clinical significance of minimal residual disease in leukemia.
Faderl S; Kantarjian HM; Talpaz M; Estrov Z
Int J Oncol; 2000 Dec; 17(6):1277-87. PubMed ID: 11078816
[TBL] [Abstract][Full Text] [Related]
2. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
Kim YJ; Kim DW; Lee S; Min CK; Goh HG; Kim SH; Lee JY; Kim YL; Kim HJ; Kim HJ; Lee JW; Kim TG; Min WS; Kim CC
Biol Blood Marrow Transplant; 2004 Oct; 10(10):718-25. PubMed ID: 15389438
[TBL] [Abstract][Full Text] [Related]
3. Detection of chromosomal translocations in leukemia-lymphoma cells by polymerase chain reaction.
Drexler HG; Borkhardt A; Janssen JW
Leuk Lymphoma; 1995 Nov; 19(5-6):359-80. PubMed ID: 8590836
[TBL] [Abstract][Full Text] [Related]
4. Detection of minimal residual disease in acute leukemia.
Sievers EL; Radich JP
Curr Opin Hematol; 2000 Jul; 7(4):212-6. PubMed ID: 10882176
[TBL] [Abstract][Full Text] [Related]
5. New approaches for the detection of minimal residual disease in acute myeloid leukemia.
van Rhenen A; Moshaver B; Ossenkoppele GJ; Schuurhuis GJ
Curr Hematol Malig Rep; 2007 May; 2(2):111-8. PubMed ID: 20425359
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
Román J; Alvarez MA; Torres A
Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
[TBL] [Abstract][Full Text] [Related]
7. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: method and significance.
Dworzak MN; Fritsch G; Panzer-Grümayer ER; Mann G; Gadner H
Leuk Lymphoma; 2000 Jul; 38(3-4):295-308. PubMed ID: 10830736
[TBL] [Abstract][Full Text] [Related]
8. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia.
Mackinnon S; Barnett L; Heller G
Bone Marrow Transplant; 1996 Apr; 17(4):643-7. PubMed ID: 8722369
[TBL] [Abstract][Full Text] [Related]
9. Application of the polymerase chain reaction for detection of minimal residual disease of hematologic malignancies.
Roth MS; Terry VH
Henry Ford Hosp Med J; 1991; 39(2):112-6. PubMed ID: 1890004
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of minimal residual disease in leukemia, advantages and pitfalls.
Cazzaniga G; Gaipa G; Rossi V; Biondi A
Ann Med; 2006; 38(7):512-21. PubMed ID: 17101542
[TBL] [Abstract][Full Text] [Related]
11. The detection and significance of minimal residual disease in chronic myeloid leukemia.
Radich JP
Medicina (B Aires); 2000; 60 Suppl 2():66-70. PubMed ID: 11188935
[TBL] [Abstract][Full Text] [Related]
12. [Detection of minimal residual disease of chronic myeloid leukemia patients after allogeneic stem cell transplantation by combination of STR-PCR with RT-PCR].
Tang XW; Wang W; Wu DP; Ruan CG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Aug; 12(4):484-8. PubMed ID: 15363137
[TBL] [Abstract][Full Text] [Related]
13. Qualitative assessment of mixed chimerism after allogeneic bone marrow transplantation with regard to leukemic relapse.
Kögler G; Hernandez A; Heyll A; Wolf HH; Wernet P
Cancer Detect Prev; 1996; 20(6):601-9. PubMed ID: 8939346
[TBL] [Abstract][Full Text] [Related]
14. [A tal-1 deletion as real-time quantitative polymerase chain reaction target for detection of minimal residual disease in T-lineage acute lymphoblastic leukemia].
Wang L; Zhang LP; Li ZG; Cheng YF; Tian KG; Lu AD
Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):170-3. PubMed ID: 15833185
[TBL] [Abstract][Full Text] [Related]
15. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Elmaagacli AH; Beelen DW; Schaefer UW
Bone Marrow Transplant; 1997 Dec; 20(12):1045-55. PubMed ID: 9466277
[TBL] [Abstract][Full Text] [Related]
16. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation.
Seriu T; Yokota S; Nakao M; Misawa S; Takaue Y; Koizumi S; Kawai S; Fujimoto T
Leukemia; 1995 Apr; 9(4):615-23. PubMed ID: 7723394
[TBL] [Abstract][Full Text] [Related]
17. Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia.
Asnafi V; Rubio MT; Delabesse E; Villar E; Davi F; Damaj G; Hirsch I; Dhédin N; Vernant JP; Varet B; Buzyn A; Macintyre E
Leukemia; 2006 May; 20(5):793-9. PubMed ID: 16541140
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease studies in acute leukemia.
Campana D
Am J Clin Pathol; 2004 Dec; 122 Suppl():S47-57. PubMed ID: 15690642
[TBL] [Abstract][Full Text] [Related]
19. Studies of minimal residual disease in acute lymphocytic leukemia.
Stock W; Estrov Z
Hematol Oncol Clin North Am; 2000 Dec; 14(6):1289-305, viii-ix. PubMed ID: 11147224
[TBL] [Abstract][Full Text] [Related]
20. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
Appelbaum FR
Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
